2025-12-20 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly (LLY) based on the data you provided:

**1) Return Rate Comparison:**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing pharmaceutical products.
*   **LLY Cumulative Return:** 305.60%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:** 199.3 (Relative Divergence: 82.6)

**Analysis:**

*   LLY has significantly outperformed the S&P 500 (VOO) over the period considered. The cumulative return of LLY is more than three times that of VOO.
*   The divergence of 199.3 indicates a large gap in performance. The relative divergence of 82.6 suggests that the current divergence is relatively high compared to historical divergences between the two assets. This means that LLY's outperformance is strong and near the upper end of its historical range compared to the S&P 500.
*   **Alpha, Beta Analysis:**
    *   The CAGR has consistently been high, with very high value in 2021-2025 periods.
    *   The MDD is also very high from 2015-2025 periods.
    *    The Alpha is very high from 2020-2025 periods.
    *   The Beta is very low from 2015-2025 periods.
    *   The Cap(B) continues to increase significantly from 2015 to 2025.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 1071.44
*   **Previous Close:** 1056.88
*   **Change:** 1.38%
*   **5-day SMA:** 1057.32
*   **20-day SMA:** 1042.56
*   **60-day SMA:** 931.17

**Analysis:**

*   The stock price is currently above all three moving averages (5-day, 20-day, and 60-day). This suggests a short-term, mid-term, and long-term uptrend.
*   The price is trending upwards, as the 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA.
*   The positive change from the previous close indicates recent upward momentum.

**3) RSI, PPO, and Expected Return Analysis:**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 55.59
*   **PPO:** -0.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Divergence Change:** 10.1 (+) (Short-term increase)
*   **Expected Return:** 51.6%

**Analysis:**

*   The MRI of 0.7 suggests a medium level of investment risk, indicating that the stock is reasonably attractive for investment.
*   An RSI of 55.59 is neutral, meaning the stock is neither overbought nor oversold.
*   A PPO of -0.23 is negligibly negative, meaning the 20-day EMA is slightly above 50-day EMA.
*   The increase in recent divergence further corroborates this analysis.
*   The Expected Return of 51.6% is exceptionally high, indicating significant potential for long-term gains compared to the S&P 500.

**4) Recent News & Significant Events:**

*   **Key Themes:**
    *   Analysts are raising price targets and highlighting the potential of Eli Lilly's obesity pipeline.
    *   The market may not be fully pricing in the dominance of Eli Lilly's weight-loss drugs.
    *   The stock has outperformed Nvidia in recent weeks.

**Analysis:**

*   The news headlines are overwhelmingly positive, focusing on the company's potential in the weight-loss drug market and analyst upgrades.
*   The positive sentiment from news articles, especially regarding weight-loss drugs, confirms the positive performance of the stock.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: 1093.22, High: 1500.00, Low: 770.00
*   **Recent Rating Changes:** Not specified, assume neutral/no changes.

**Analysis:**

*   The analyst consensus is a "Buy," indicating a positive outlook on the stock.
*   The average target price suggests a potential upside from the current price of 1071.44.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출     |
| ----------- | ----- | -------- |
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3  | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Analysis:**

*   The table displays a general trend of increasing revenue and EPS over the recent quarters, indicating strong business performance.
*   The two different EPS and 매출 numbers on 2025-10-30 need to be reviewed to make sure that the data is correct.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ----------- | --------- | --------------- |
| 2025-09-30 | $17.60B | 82.91%         |
| 2025-06-30 | $15.56B | 84.27%         |
| 2025-03-31 | $12.73B | 82.53%         |
| 2024-12-31 | $13.53B | 82.24%         |
| 2024-09-30 | $11.44B | 81.02%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
| ----------- | --------- | -------- |
| 2025-09-30 | $23.79B | 23.46%   |
| 2025-06-30 | $18.27B | 30.98%   |
| 2025-03-31 | $15.76B | 17.50%   |
| 2024-12-31 | $14.19B | 31.07%   |
| 2024-09-30 | $14.24B | 6.81%    |

**Analysis:**

*   **Revenue and Profitability:**  Revenue has been consistently increasing, and the profit margin remains very high, indicating efficient operations.
*   **Capital and Profitability:**  Equity is growing steadily, with strong ROE figures, reflecting effective utilization of shareholder equity.

**7) Comprehensive Analysis:**

Eli Lilly (LLY) shows a very promising profile based on the provided data:

*   **Strong Performance:**  LLY has significantly outperformed the S&P 500, driven by positive developments in the company, especially in the weight-loss drug sector.
*   **Positive Momentum:**  The stock is in a clear uptrend, supported by moving averages, recent price action, and a recent short-term increase.
*   **Analyst Confidence:**  Analysts have a "Buy" consensus and are raising price targets, suggesting further upside potential.
*   **Strong Financials:**  Revenue, EPS, and profitability metrics are trending positively, supported by robust equity growth and ROE.
*   **Investment Recommendation:** MRI indicates that the stock is good for investment.
*   **Potential Risks:** The high MDD could potentially be a point to consider.

**Overall:** LLY appears to be a strong investment candidate based on the data provided. The stock exhibits positive momentum, robust financial performance, and strong analyst confidence. The potential of the weight-loss drug pipeline appears to be a significant driver of this positive outlook.

**Disclaimer:** This analysis is based solely on the data provided and should not be considered financial advice. Investors should conduct their own research and consider their individual circumstances before making investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.